MA47601A - Faible viscosité, formulations d'évolocumab à haute concentration et leurs procédés de préparation - Google Patents

Faible viscosité, formulations d'évolocumab à haute concentration et leurs procédés de préparation

Info

Publication number
MA47601A
MA47601A MA047601A MA47601A MA47601A MA 47601 A MA47601 A MA 47601A MA 047601 A MA047601 A MA 047601A MA 47601 A MA47601 A MA 47601A MA 47601 A MA47601 A MA 47601A
Authority
MA
Morocco
Prior art keywords
high concentration
low viscosity
preparation procedures
evolocumab formulations
evolocumab
Prior art date
Application number
MA047601A
Other languages
English (en)
Inventor
Elaheh Binabaji
Chio Mui Chan
Huanchun Cui
Sekhar Kanapuram
Christopher James Sloey
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA47601A publication Critical patent/MA47601A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047601A 2017-02-22 2018-02-22 Faible viscosité, formulations d'évolocumab à haute concentration et leurs procédés de préparation MA47601A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762462266P 2017-02-22 2017-02-22

Publications (1)

Publication Number Publication Date
MA47601A true MA47601A (fr) 2020-01-01

Family

ID=61617101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047601A MA47601A (fr) 2017-02-22 2018-02-22 Faible viscosité, formulations d'évolocumab à haute concentration et leurs procédés de préparation

Country Status (18)

Country Link
US (2) US11464857B2 (fr)
EP (1) EP3585821A1 (fr)
JP (1) JP7377596B2 (fr)
KR (1) KR20190120257A (fr)
CN (1) CN110536906A (fr)
AR (2) AR110938A1 (fr)
AU (1) AU2018224095B2 (fr)
BR (1) BR112019017393A8 (fr)
CA (1) CA3053394A1 (fr)
CL (1) CL2019002362A1 (fr)
EA (1) EA201991951A1 (fr)
IL (1) IL268515B2 (fr)
MA (1) MA47601A (fr)
MX (1) MX2019009952A (fr)
SG (1) SG11201907505TA (fr)
TW (1) TWI833690B (fr)
UY (1) UY37611A (fr)
WO (1) WO2018156741A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN113660927A (zh) * 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度
AU2020407188B2 (en) 2019-12-17 2026-01-22 Amgen Inc. Container visual inspection assembly and method
CN115297838A (zh) * 2020-02-24 2022-11-04 麦迪穆医学免疫有限责任公司 抗内皮脂肪酶抗体的制剂
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
CA3214867A1 (fr) * 2021-04-09 2022-10-13 Courtney O'DELL Excipients d'amelioration de la performance et methodes de reduction de la viscosite et d'augmentation de la stabilite de formulations biologiques
CA3259215A1 (fr) * 2022-06-13 2023-12-21 Celanese Eva Performance Polymers Llc Dispositif implantable monolithique pour libération prolongée d'un anticorps
WO2025265012A1 (fr) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprenant des anticorps anti-pcsk9
WO2026159667A1 (fr) 2025-01-24 2026-07-30 Hovione Farmaciência Sa Sucres synthétiques en tant qu'activateurs pour la réduction de la viscosité de molécules biologiques hautement concentrées

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
EP1028748B1 (fr) 1997-11-07 2003-05-02 Chiron Corporation Compositions pour obtenir une solubilite amelioree du facteur igf-i
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
WO2001074397A1 (fr) 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
PT1343518E (pt) 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
KR100911951B1 (ko) 2001-08-23 2009-08-13 젠맵 에이/에스 인터루킨 15 (ｉｌ-15)에 대하여 특이적인 인간 항체
CA2476934C (fr) 2002-02-27 2009-06-16 Immunex Corporation Composition stabilisee du fragment fc et du recepteur tnf comprenant de l'arginine
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
CA2651453C (fr) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. Analogues d'acides nucleiques bicycliques modifies en 5'
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
RU2558821C2 (ru) 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
EP2863951A1 (fr) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Formulation pharmaceutique destinée à un anticorps thérapeutique
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
CN121371151A (zh) * 2014-12-03 2026-01-23 瑞士杰特贝林生物制品有限公司 具有增加的稳定性的包含免疫球蛋白的药物产品
IL307684B2 (en) * 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
BR112019017393A2 (pt) 2020-04-14
TW201841650A (zh) 2018-12-01
KR20190120257A (ko) 2019-10-23
UY37611A (es) 2018-08-31
IL268515B1 (en) 2024-06-01
SG11201907505TA (en) 2019-09-27
IL268515B2 (en) 2024-10-01
US20230226177A1 (en) 2023-07-20
IL268515A (en) 2019-09-26
TWI833690B (zh) 2024-03-01
US12404344B2 (en) 2025-09-02
WO2018156741A1 (fr) 2018-08-30
CN110536906A (zh) 2019-12-03
BR112019017393A8 (pt) 2022-03-03
US11464857B2 (en) 2022-10-11
EA201991951A1 (ru) 2020-01-21
JP7377596B2 (ja) 2023-11-10
KR20240060732A (ko) 2024-05-08
AU2018224095A1 (en) 2019-08-22
AR125766A2 (es) 2023-08-09
CA3053394A1 (fr) 2018-08-30
CL2019002362A1 (es) 2019-11-29
AU2018224095B2 (en) 2025-02-27
MX2019009952A (es) 2019-10-14
US20180237501A1 (en) 2018-08-23
JP2018154616A (ja) 2018-10-04
EP3585821A1 (fr) 2020-01-01
AR110938A1 (es) 2019-05-15

Similar Documents

Publication Publication Date Title
EP3713560A4 (fr) Composés bêta-hydroxybutyrate non racémiques et compositions enrichies en l'énantiomère r, et leurs procédés d'utilisation
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
EP3758671A4 (fr) 1,2-alcanediols naturels, compositions comportant des 1,2-alcanediols naturels et leurs procédés de préparation
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
EP3310339A4 (fr) Formulations ophtalmiques d'inhibiteurs de tyrosine kinase, leurs procédés d'utilisation, et leurs procédés de préparation
EP3645054A4 (fr) Compositions à base de crispr/cas-adénine désaminase, systèmes et procédés d'édition ciblée d'acides nucléiques
EP3356522A4 (fr) Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
WO2015160843A8 (fr) Activateurs des canaux ioniques et leurs procédés d'utilisation
EP3380096A4 (fr) Compositions d'huile de cannabis et leurs procédés de préparation
EP3390598A4 (fr) Compositions nettoyantes à épaississement ainsi qu'applications et procédés de préparation associés
EP3280712A4 (fr) Composés conjugués d'acide ursodésoxycholique, de berbérine ou de l-carnitine, et compositions et procédés correspondants
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MX389802B (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
EP3458531A4 (fr) Compositions de revêtement et leurs procédés de préparation
EP3381469A4 (fr) Conjugué anticorps-médicament anti-erbb2 et composition à base de celui-ci, procédé de préparation associé et leur application
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
MA52098A (fr) Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
EP3606929A4 (fr) Nucléotides d'ester de bêta-nicotinate et leurs procédés de préparation
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EP3328800A4 (fr) Compositions polymères inhibant le tartre, mélanges et leurs méthodes d'utilisation
EP3387119A4 (fr) Compositions et méthodes améliorées d'administration virale de néoépitopes et leurs utilisations
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP3393459A4 (fr) Compositions de nanoémulsion de fluorocarbure et procédés de préparation et d'utilisation associés
WO2017075171A3 (fr) Agents d'imagerie cest à base de dendrimères pamam et leurs utilisations